EU clears first allogeneic stem cell therapy
TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union.
Read More
Tag: Cx601
Takeda/Tigenix’ stem cell therapy hits targets in Crohn’s trial
Takeda and TiGenix’ stem cell therapy has shown promise in inducing remission of perianal fistulas in patients with Crohn’s disease, according findings of a late-stage trial published in The Lancet.
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
